There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
The FDA Drug Labels for trazodone (PO) do not address this question.
From the Research
Efficacy of Trazodone for Anxiety
- Trazodone is often used off-label for various conditions, including Generalised Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder, and Obsessive-Compulsive Disorder 1.
- The medication has been shown to be effective in reducing anxiety symptoms in patients with major depressive disorder, with some studies suggesting it may be more effective than selective serotonin reuptake inhibitors (SSRIs) in this regard 2.
- A naturalistic study found that trazodone in extended release formulation was more effective than SSRIs in reducing anxiety symptoms in patients with major depressive disorder 2.
- Trazodone has also been found to be effective in treating adjustment disorders, with a significant decrease in anxiety symptoms observed on the 7th day of therapy 3.
- Experts have identified the effectiveness of trazodone in patients with major depressive disorder and anxiety symptoms, suggesting it may be a useful treatment option for this population 4.
Mechanism of Action
- Trazodone's 5HT2A receptor antagonistic action may contribute to its anxiolytic effects, as well as its ability to prevent the occurrence of initial and long-term side effects of SSRIs, such as anxiety and insomnia 1.
- The medication's pharmacodynamic properties allow it to avoid the side effects of insomnia, anxiety, and sexual dysfunction often associated with SSRIs 5.
Clinical Implications
- Trazodone may be a useful treatment option for patients with anxiety symptoms, particularly those with major depressive disorder or adjustment disorders 2, 3, 4.
- The medication's efficacy and safety profile make it a potential alternative to SSRIs for patients who experience adverse effects or inadequate response to these medications 5, 2.